CGBIO gets bone graft BMP-2 ‘NOVOSIS’ approval in India The Korean regenerative biopharmaceutical firm CGBIO said on November 2, 2020 that India’s Central Drugs Standard Control Organization (CDSCO) authorized the sale… 2020-11-17 cgbio
CGBIO to supply NOVOSIS to LifeHealthcare in Australia rhBMP-2 The Korean regenerative biopharmaceutical firm CGBIO announced an agreement with Australia’s leading independent medical device distributor, LifeHealthcare, on September 16, 2020 that… 2020-10-12 cgbio
CGBIO moves its headquarters to Hannam-dong global culture center Relocation of headquarters in the midst of increasing employment and business expansion CGBIO adopts the name of ‘Global Challenge Center’ as headquarters… 2020-08-25 cgbio
CGBIO attains CE certificates of EU for three medical devices The three types of medical devices are ExcelOS Inject, Facetem S, and CG GEL. CE is an integrated proof that the product… 2020-05-22 cgbio
CGBIO opens new cGMP ‘S-CAMPUS’ plant in Hyangnam A manufacturing plant that does not look like a manufacturing plant due to the use of environment-friendly materials CGBIO to use S-CAMPUS… 2019-10-02 cgbio
CGBIO signs $500 million deal with Japan’s Nippon Zoki for NOVOSIS Putty CGBIO overcomes Japan’s conservative mindset to reject any change in its medical industry. CGBIO’s global expansion strategies are in full swing. … 2019-09-23 cgbio
CGBIO inks a $30 million deal with Eris Lifesciences for NOVOSIS CGBIO aims to make inroads into Latin American markets through an agreement of KRW 3.6 billion with a Brazilian company for an… 2019-09-23 cgbio
CGBio to supply bone grafts to Indonesia CGBIO is poised to pave the way to enter a new market with a lucrative potential. ‘The Korean regenerative biopharmaceutical firm… 2019-02-20 cgbio
CG Bio Receives Approval for 3D Printed Cheekbones Traditionally, there has always been some risk involved when implanting anything new into the human body, whether it’s an organ transplant, a… 2018-04-19 cgbio
Posterolateral lumbar fusion results similar between E.BMP-2, autogenous bone graft The fusion rate of Escherichia coli-derived recombinant human bone morphogenetic protein-2 following posterolateral lumbar fusion was similar to autogenous iliac bone graft, according… 2018-02-26 cgbio